Cellular heterogeneity in pancreatic cancer: the different faces of gremlin action  

作　　者：Aristidis Moustakas J.Matthias Löhr Rainer L.Heuchel 

机构地区：[1]Department of Medical Biochemistry and Microbiology,Uppsala University,Uppsala,Sweden [2]Department of Clinical Intervention and Technology(CLINTEC),Karolinska Institutet,Stockholm,Sweden

出　　处：《Signal Transduction and Targeted Therapy》2022年第11期3992-3994,共3页信号转导与靶向治疗（英文）

基　　金：CancerFonden(RLH 201356 PjF,AM CAN2021/1506Pj01H);Radiumhemmets Foksningsfonder/RahFo(JML 191213).

摘　　要：A recent publication in Nature by Lan et al.,presented GREM1(gremlin 1)as an important regulatory node of cellular plasticity in pancreatic ductal adenocarcinoma(PDAC).1 Knockout experiments in mice point to an important role of Grem1 in retaining an epithelial,differentiated phenotype of pancreatic cancer cells presumably by inhibiting BMP signalling.

关 键 词：al. cancer INHIBITING 

分 类 号：R735.9[医药卫生—肿瘤]